Development of a mass spectrometry based diagnostic test for atherosclerosis

D. G. Harman; M. Fernando; A. O'Loughlin

Development of a mass spectrometry based diagnostic test for atherosclerosis

D. G. Harman, M. Fernando, A. O'Loughlin

Western Sydney University

Research output: Chapter in Book / Conference Paper › Conference Paper

Abstract

![CDATA[Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for 32% of mortality. In Australia CAD causes 45,000 deaths annually, costing the health system $8 billion per year. CAD is caused by atherosclerosis, the build-up of plaque inside arteries. Diagnosis of CAD presents several problems: it is expensive, imparts a significant radiation load to the patient, and is not sensitive enough to detect the disease in its early stages. We are developing an LCMS/MS method which looks promising as a sensitive, specific, inexpensive and non-invasive diagnostic test for CAD at a stage where intervention will be effective.]]

Original language	English
Title of host publication	The 27th Australian and New Zealand Society for Mass Spectrometry Conference (ANZSMS27). Conference Abstracts, Oral Presentations, 30 January-3 February 2019, Auckland, N. Z.
Publisher	ANZSMS
Pages	12-12
Number of pages	1
Publication status	Published - 2019
Event	Australian and New Zealand Society for Mass Spectrometry. Conference - Duration: 1 Jan 2023 → …

Conference

Conference	Australian and New Zealand Society for Mass Spectrometry. Conference
Period	1/01/23 → …

Cite this

@inproceedings{c9b8e42e109744c491779bfc61d81461,

title = "Development of a mass spectrometry based diagnostic test for atherosclerosis",

abstract = "![CDATA[Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for 32% of mortality. In Australia CAD causes 45,000 deaths annually, costing the health system $8 billion per year. CAD is caused by atherosclerosis, the build-up of plaque inside arteries. Diagnosis of CAD presents several problems: it is expensive, imparts a significant radiation load to the patient, and is not sensitive enough to detect the disease in its early stages. We are developing an LCMS/MS method which looks promising as a sensitive, specific, inexpensive and non-invasive diagnostic test for CAD at a stage where intervention will be effective.]]",

author = "Harman, {D. G.} and M. Fernando and A. O'Loughlin",

year = "2019",

language = "English",

pages = "12--12",

booktitle = "The 27th Australian and New Zealand Society for Mass Spectrometry Conference (ANZSMS27). Conference Abstracts, Oral Presentations, 30 January-3 February 2019, Auckland, N. Z.",

publisher = "ANZSMS",

note = "Australian and New Zealand Society for Mass Spectrometry. Conference ; Conference date: 01-01-2023",

}

Harman, DG, Fernando, M & O'Loughlin, A 2019, Development of a mass spectrometry based diagnostic test for atherosclerosis. in The 27th Australian and New Zealand Society for Mass Spectrometry Conference (ANZSMS27). Conference Abstracts, Oral Presentations, 30 January-3 February 2019, Auckland, N. Z.. ANZSMS, pp. 12-12, Australian and New Zealand Society for Mass Spectrometry. Conference, 1/01/23.

Development of a mass spectrometry based diagnostic test for atherosclerosis. / Harman, D. G.; Fernando, M.; O'Loughlin, A.
The 27th Australian and New Zealand Society for Mass Spectrometry Conference (ANZSMS27). Conference Abstracts, Oral Presentations, 30 January-3 February 2019, Auckland, N. Z.. ANZSMS, 2019. p. 12-12.

Research output: Chapter in Book / Conference Paper › Conference Paper

TY - GEN

T1 - Development of a mass spectrometry based diagnostic test for atherosclerosis

AU - Harman, D. G.

AU - Fernando, M.

AU - O'Loughlin, A.

PY - 2019

Y1 - 2019

N2 - ![CDATA[Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for 32% of mortality. In Australia CAD causes 45,000 deaths annually, costing the health system $8 billion per year. CAD is caused by atherosclerosis, the build-up of plaque inside arteries. Diagnosis of CAD presents several problems: it is expensive, imparts a significant radiation load to the patient, and is not sensitive enough to detect the disease in its early stages. We are developing an LCMS/MS method which looks promising as a sensitive, specific, inexpensive and non-invasive diagnostic test for CAD at a stage where intervention will be effective.]]

AB - ![CDATA[Coronary artery disease (CAD) is the leading cause of death worldwide, accounting for 32% of mortality. In Australia CAD causes 45,000 deaths annually, costing the health system $8 billion per year. CAD is caused by atherosclerosis, the build-up of plaque inside arteries. Diagnosis of CAD presents several problems: it is expensive, imparts a significant radiation load to the patient, and is not sensitive enough to detect the disease in its early stages. We are developing an LCMS/MS method which looks promising as a sensitive, specific, inexpensive and non-invasive diagnostic test for CAD at a stage where intervention will be effective.]]

UR - https://hdl.handle.net/1959.7/uws:71086

M3 - Conference Paper

SP - 12

EP - 12

BT - The 27th Australian and New Zealand Society for Mass Spectrometry Conference (ANZSMS27). Conference Abstracts, Oral Presentations, 30 January-3 February 2019, Auckland, N. Z.

PB - ANZSMS

T2 - Australian and New Zealand Society for Mass Spectrometry. Conference

Y2 - 1 January 2023

ER -

Development of a mass spectrometry based diagnostic test for atherosclerosis

Abstract

Conference

Other files and links

Fingerprint

Cite this